VKTX logo

VIKING THERAPEUTICS INC

VKTXNASDAQ
🏆 #1413 by market capEarnings Oct 28 · PostUS Equity
$370.22▲ $5.26 (+1.42%)
Simulated price
🔔
Track VKTX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.4%
7d▲ 806.7%
14d▲ 1135.7%
30d▲ 1051.5%
ytd▲ 952.7%
1y▲ 1334.7%
🏦Market Cap
$4.44B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
80
Good

Trading Snapshot

Day Range
$366.79 – $374.83
52-Week Range
$24.88 – $43.15
Volume
$3.81B
Avg Volume
$3.65B
Shares Outstanding
116.7M
Next Earnings
Dec 14, 2026

Fundamentals Snapshot

Annual Revenue
$457M
Last Q Revenue
$116M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-4.66
Dividend Yield
—
Dilution (1yr)
+2.4%

Why Investors Own VKTX

  • ✓High-growth profile — revenue up +32.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 52% gross margin and 14% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

VKTX logo

VIKING THERAPEUTICS INC

VKTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$393M▲ +160.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$279M▲ +217.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
114.0M▲ +2.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$166M▲ +$140M YoY
StockOtter · stockotter.space

About VIKING THERAPEUTICS INC

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
80/100

Analyst Price Target

ⓘ
Average Target
$464.53
▲ +25.5% Upside
High Target$520.13
Low Target$409.47
Based on 11 analysts

Latest News & Updates

🚀
Reuters·2h ago

VIKING THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift VKTX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

VIKING THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.